INHALE: Investigation of Health outcomes in Australian Lung cancer

Not Applicable

Recruiting

• Conditions: ung cancer; Lung cancer; Cancer - Lung - Mesothelioma; Cancer - Lung - Non small cell; Cancer - Lung - Small cell

• Registration Number: ACTRN12620000376943
• Lead Sponsor: The Walter and Eliza Hall Institute of Medical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-03-18
• Last Update Posted: 14 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

1. Histologically or cytologically confirmed diagnosis of lung cancer, or high clinical suspicion of a diagnosis of lung cancer based on radiological findings
2. Patients aged 18 years or above

Exclusion Criteria

None

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical data collection of 1000 lung cancer patients to determine real world clinical outcomes and tumour characteristics in routine clinical practice. This outcome is being assessed by entry into medical records. [Data will be collected at up to 6 time points for a maximum of 5 years; diagnosis, surgery, surveillance, chemotherapy, radiotherapy and recurrence. Time point is at the end of the 5 year data collection period. ]

Secondary Outcome Measures

Name	Time	Method
Treatment patters of patients diagnosed with lung cancer in routine clinical practice. This outcome is being assessed by entry into medical records. [Data will be collected at up to 6 time points for a maximum of 5 years; diagnosis, surgery, surveillance, chemotherapy, radiotherapy and recurrence. Time point is at the end of the 5 year data collection period. ];Overall survival of patients diagnosed with Lung Cancer in Ausralia after treatment. This outcome is being assessed from each patients medical record[Data will be collected at up to 6 time points for a maximum of 5 years; diagnosis, surgery, surveillance, chemotherapy, radiotherapy and recurrence. Time point is at the end of the 5 year data collection period. ]